Amarin | AMRN - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 645M 69M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
DBV Technologies USD 461K 323.71K 2025-03
Esperion Therapeutics USD 22.64M 585K 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
Halozyme Therapeutics USD 5.51M 597K 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03